drugset / Trial / NCT04614298
A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is assessing the efficacy and safety of brodalumab in Chinese subjects with moderate to severe plaque psoriasis.
Timeline
- Start
- 2021-01
- Primary completion
- 2022-02
- Completion
- 2022-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |